Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Surufatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Surufatinib SCHEMBL29366533 | 1.00 | KDR (1.00) | KDRFLT1FGFR1FLT4FLT3 | |
| Surufatinib SCHEMBL29363337 | 1.00 | KDR (1.00) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL28690029 | 0.93 | KDR (0.87) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL4882838 | 0.89 | KDR (0.80) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14048275 | 0.87 | KDR (0.77) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL21921266 | 0.87 | KDR (0.77) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL1811283 | 0.87 | KDR (0.76) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL29413031 | 0.87 | KDR (0.76) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024559 | 0.85 | KDR (0.74) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024540 | 0.85 | KDR (0.73) | KDRFLT1FGFR1FLT4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107613984-B | Pharmaceutical composition and use thereof | 和记黄埔医药（上海）有限公司 | 2021-04-30 | — | — | CN | claimed |
| EP-3302483-B1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2020-04-15 | — | — | EP | claimed |
| US-20190276439-A1 | METHOD OF TREATING SOLID TUMORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-09-12 | — | — | US | claimed |
| US-20180153890-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-06-07 | — | — | US | claimed |
| US-8946249-B2 | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-02-03 | — | — | US | claimed |
| EP-2504331-B1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHISON MEDIPHARMA LTD (CN) | 2014-11-12 | — | — | EP | claimed |
| US-20140200232-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-07-17 | — | — | US | claimed |
| US-8658658-B2 | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-02-25 | — | — | US | claimed |
| US-20120270889-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHMED LIMITED (CN) | 2012-10-25 | — | — | US | claimed |
| EP-2504331-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | Hutchison Medipharma Limited (CN) | 2012-10-03 | — | — | EP | claimed |
| WO-2011060746-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-05-26 | — | — | WO | claimed |
| CN-113876715-B | Solid dispersion of soratinib, tablet thereof and preparation method thereof | 和记黄埔医药（苏州）有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220073642-A1 | METHODS OF USING SURUFATINIB IN TREATING ADVANCED PANCREATIC AND EXTRA-PANCREATIC NEUROENDOCRINE TUMORS | HUTCHISON MEDIPHARMA LIMITED | 2022-03-10 | — | — | US | disclosed |
| US-20220073642-A1 | METHODS OF USING SURUFATINIB IN TREATING ADVANCED PANCREATIC AND EXTRA-PANCREATIC NEUROENDOCRINE TUMORS | HUTCHISON MEDIPHARMA LIMITED | 2022-03-10 | — | — | US | disclosed |
| CN-114085214-A | Sofantinib impurity and preparation method and application thereof | 和记黄埔医药（上海）有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20120270889-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHMED LIMITED (CN) | 2012-10-25 | — | — | US | disclosed |
| US-20120270889-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHMED LIMITED (CN) | 2012-10-25 | — | — | US | disclosed |
| EP-2504331-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | Hutchison Medipharma Limited (CN) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011060746-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060746-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276439-A1 | METHOD OF TREATING SOLID TUMORS | FGFR1, CSF1R, FLT1 | KDR 15/4885FLT1 3/4885FGFR1 1/4885 |
| US-20220073642-A1 | METHODS OF USING SURUFATINIB IN TREATING ADVANCED PANCREATIC AND EXTRA-PANCREATIC NEUROENDOCRINE TUMORS | RNASE1, AMY2A, PNLIP | KDR 2096/4885FLT1 2948/4885FGFR1 1068/4885 |
| US-20180153890-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | PDE10A, FURIN, PCSK9 | KDR 4077/4885FLT1 3571/4885FGFR1 3522/4885 |
| US-20140200232-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | ADCYAP1R1, CYP2F1, CYP4A11 | KDR 4513/4885FLT1 3385/4885FGFR1 1728/4885 |
| US-20120270889-A1 | COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR PREPARATION AND USE | ADCYAP1R1, CYP2F1, CYP4A11 | KDR 4513/4885FLT1 3385/4885FGFR1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.